Finally, the identification of c-erbB2 as the most highly differentially expressed gene in USPC suggest that targeting HER-2/neu by rhuMAb anti-HER-2 (Herceptin) may be potentially highly beneficial against these biologically aggressive and chemotherapy-resistant variants of endometrial cancer. Here, ERBB2 is linked to endometrial cancer.